secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2026-05-11T20:03:51+00:00
Accession:  0001339970-26-000027
Event type: regulatory
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma to launch new Phase 3 study of efzofitimod in pulmonary sarcoidosis after FDA feedback
--------------------------------------------------------------------------------

- Cash, cash equivalents, and investments totaled $68.3M as of March 31, 2026 (unaudited).
- FDA Type C meeting endorsed FVC as primary endpoint and KSQ-Lung as key secondary in new Phase 3.
- New trial to enroll ~372 patients with restrictive lung disease (FVC ≤80% predicted) on stable corticosteroids.
- Dosing changed to 5.0 mg/kg every 3 weeks (from every 4 weeks) with enhanced safety monitoring.
- Company plans to submit IND for this Phase 3 study in June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000133997026000027/0001339970-26-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000133997026000027/atyr-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001339970-26-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer